Thomas FitzGerald to Carcinoma, Non-Small-Cell Lung
This is a "connection" page, showing publications Thomas FitzGerald has written about Carcinoma, Non-Small-Cell Lung.
Connection Strength
0.526
-
Varlotto JM, Sun Z, Ky B, Upshaw J, Fitzgerald TJ, Diehn M, Lovly C, Belani C, Oettel K, Masters G, Harkenrider M, Ross H, Ramalingam S, Pennell NA. A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181. Clin Lung Cancer. 2022 11; 23(7):547-560.
Score: 0.176
-
Varlotto JM, Sun Z, Ky B, Upshaw J, Katz SI, Fitzgerald TJ, Wakelee H, Diehn M, Mankoff DA, Lovely C, Belani C, Oettel K, Masters G, Ramalingam S, Pennell NA. A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study. Oncologist. 2021 06; 26(6):523-532.
Score: 0.160
-
Wozniak AJ, Moon J, Thomas CR, Kelly K, Mack PC, Gaspar LE, Raben D, Fitzgerald TJ, Pandya KJ, Gandara DR. A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Combination of Bevacizumab (NSC-704865) in Patients With Inoperable Locally Advanced Stage III Non-Small-Cell Lung Cancer: SWOG S0533. Clin Lung Cancer. 2015 Sep; 16(5):340-7.
Score: 0.105
-
Hoang T, Dahlberg SE, Schiller JH, Mehta MP, Fitzgerald TJ, Belinsky SA, Johnson DH. Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study. J Clin Oncol. 2012 Feb 20; 30(6):616-22.
Score: 0.085